This past week, some of the world’s biggest R&D players doubled down on growth — Johnson & Johnson pledged $55B in U.S. investments, and AstraZeneca announced a new global R&D center in China — while others tightened their belts. Audi and Siemens both revealed significant job cuts, underscoring the shifting priorities in a fast-paced market…
In 2024, the US and Europe led in pharma value creation while GLP-1s disrupted the landscape
GLP-1 juggernauts Eli Lilly and Novo Nordisk, whose combined $1.18 trillion market cap now exceeds Johnson & Johnson, AbbVie, and Merck combined, have staked their claim as stock market darlings. This momentum is particularly evident in Novo Nordisk’s remarkable trajectory, reaching a $604 billion market capitalization by March 2024 and securing its position as the…
Cerenovus President Mark Dickinson on the future of stroke care
Cerenovus President Mark Dickinson forecasts the innovative technologies that will advance stroke care in the coming years. It’s getting harder to beat aspiration systems for fast and simple thrombectomies to remove blood clots that are blocking oxygen from a stroke patient’s brain. That’s according to Cerenovus Worldwide President Mark Dickinson, who discussed the future of…